# Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer

> **NCT01090128** · PHASE1 · TERMINATED · sponsor: **University of Utah** · enrollment: 27 (actual)

## Conditions studied

- Stages II-III Breast Cancer

## Interventions

- **DRUG:** Nanoparticle Albumin Bound Paclitaxel
- **DRUG:** doxorubicin
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT01090128
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2017-03-24
- **Final completion:** 2017-03-24
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Drug Manufacturer withdrew support for studies not in metastatic breast cancer
- **Last updated:** 2017-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01090128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01090128, "Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01090128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*